Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTECT-1 obefazimod for moderately to severely active ulcerative colitis
NL-OMON58710Phase 3Completed
- Sponsor
- Abivax
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Obefazimod with Placebo (2 arms). Primary endpoints: Endoscopic improvement at week 8 and Symptomatic remission at week 8. Started Oct 2023; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON58710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58710.